Sequencing-Based Fetal Testing Market Heats up as Verinata Plans 2012 Launch for Down Syndrome Dx | GenomeWeb

By Monica Heger

This story was originally published on May 2.

Verinata Health, formerly Artemis Health, last week published an initial validation study of a sequencing-based test to detect fetal aneuploidy in maternal blood and said it plans to launch a test by early next year for the detection of trisomy 21 and potentially other aneuploidies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.